AXIM® Biotechnologies Signs LOI for Distribution of Products Throughout Australia and New Zealand
13. September 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that it has signed a...
AXIM® Biotechnologies Enters Canadian Market Through New Exclusive Distribution and License Agreement With Revive Therapeutics
27. August 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech or the “Company”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that...
AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South Korea
03. April 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), a world leader in cannabinoid research and development, today announced that it has...
AXIM Biotechnologies Reports Year End 2017 Results
19. März 2018 16:15 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced financial results for...
AXIM Biotech Enters Into Distribution Agreement for Proprietary Cannabinoid-Based Nutraceutical Chewing Gum Product CanChew+ Throughout Thailand
06. Februar 2018 10:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM) (“AXIM”), the world leader in cannabinoid research and development, announced today that it has entered into a...
AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis
02. August 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a...
AXIM Biotech Receives Schedule 1 Permit to Move Forward With Development of MedChew Rx Pharmaceutical Chewing Gum
02. Mai 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, May 02, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company’s product...
AXIM Biotech Announces the Production of CanChew Plus™, the Next Generation Controlled Release CBD Chewing Gum
01. März 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, began production of CanChew Plus™, the next...
AXIM Biotech to Attend the 19th Annual BIO CEO & Investor Conference in New York
09. Februar 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that George E. Anastassov,...
Axim® Biotechnologies, Inc. Donates Flagship CanChew Gum to U.S. Pain Foundation to Help Chronic Pain Sufferers
22. November 2016 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has donated...